Pharmaceuticals, Biotechnology and Life Sciences
Abzena, a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has reported that one of the ‘Abzena inside’ Composite Human Antibody products for the treatment of neurodegenerative conditions has moved to Phase II clinical trial.
A research group from University College London’s (UCL’s) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to continue developing of a new treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.
Abzena has signed a deal with University College London (UCL) to manufacture Magacizumab, an antibody created with its ‘Abzena inside’ Composite Human Antibody technology.
Abzena has made application to the London Stock Exchange for the admission of 715,772 new ordinary shares of £0.002 each (‘New Ordinary Shares’) to trading on AIM.
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
Abzena has granted USA-based Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, for exploitation in…
Abzena has issued a statement in which it notes that during the conference call to accompany Gilead Sciences Inc.’s (‘Gilead’) announcement of third quarter
Faron and Abzena in cancer medicine Clevegen manufacture deal
Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders
Abzena plc will buy Philadelphia-based The Chemistry Research Solution LLC (TCRS), a specialist contract chemistry and bioconjugation company, specialized in producing and analyzing antibody drug conjugates (DACs), for $15 million